בריפלקס PN 250

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

COAGULATION FACTOR II (HUMAN); COAGULATION FACTOR IX (HUMAN- RFIXFC); COAGULATION FACTOR VII (HUMAN); COAGULATION FACTOR X (HUMAN); PROTEIN C; PROTEIN S ANTIGEN

Commercializzato da:

CSL BEHRING LTD., ISRAEL

Codice ATC:

B02BD01

Forma farmaceutica:

אבקה וממס להכנת תמיסה להזרקה

Composizione:

COAGULATION FACTOR II (HUMAN) 200 - 480 IU; COAGULATION FACTOR VII (HUMAN) 100 - 250 IU; COAGULATION FACTOR IX (HUMAN- RFIXFC) 200 - 310 IU; COAGULATION FACTOR X (HUMAN) 220 - 600 IU; PROTEIN C 150 - 450 IU; PROTEIN S ANTIGEN 120 - 380 IU

Via di somministrazione:

תוך-ורידי

Tipo di ricetta:

מרשם נדרש

Prodotto da:

CSL BEHRING GmbH, GERMANY

Gruppo terapeutico:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Area terapeutica:

COAGULATION FACTOR IX, II, VII AND X IN COMBINATION

Indicazioni terapeutiche:

-Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.

Data dell'autorizzazione:

2017-03-31